These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2654132)

  • 41. Analysis of metastatic competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes.
    Pohl J; Radler-Pohl A; Franks LM; Schirrmacher V
    J Cancer Res Clin Oncol; 1988; 114(4):373-9. PubMed ID: 3410877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity.
    Dear AE; Medcalf RL
    Biochim Biophys Acta; 2000 Jun; 1492(1):15-22. PubMed ID: 11004477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
    Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS
    Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
    Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
    Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
    Ossowski L; Clunie G; Masucci MT; Blasi F
    J Cell Biol; 1991 Nov; 115(4):1107-12. PubMed ID: 1659573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products.
    Caulín C; López-Barcons L; Gonzáles-Garrigues M; Navarro P; Lozano E; Rodrigo I; Gamallo C; Cano A; Fabra A; Quintanilla M
    Mol Carcinog; 1996 Feb; 15(2):104-14. PubMed ID: 8599577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
    Haeckel C; Krueger S; Roessner A
    Int J Cancer; 1998 Jul; 77(1):153-60. PubMed ID: 9639407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro malignant conversion of low-grade rat urinary bladder carcinoma cells by exposure to N-methyl-N-nitrosourea.
    Azuma M; Momose H; Oyasu R
    Cancer Res; 1990 Nov; 50(21):7062-7. PubMed ID: 2208174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No acquisition of metastatic capacity of R1H rhabdomyosarcoma upon transfection with c-Ha-ras oncogene.
    Baisch H; Collard J; Zywietz F; Jung H
    Invasion Metastasis; 1990; 10(4):193-207. PubMed ID: 2192992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
    Mitra SK; Lim ST; Chi A; Schlaepfer DD
    Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    See WA
    J Natl Cancer Inst; 1998 Sep; 90(17):1303. PubMed ID: 9731738
    [No Abstract]   [Full Text] [Related]  

  • 54. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
    Testa JE
    Cancer Res; 1992 Oct; 52(20):5597-603. PubMed ID: 1327511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced expression of the urokinase-type plasminogen activator gene and reduced colony formation in soft agar by ectopic expression of PU.1 in HT1080 human fibrosarcoma cells.
    Kondoh N; Yamada T; Kihara-Negishi F; Yamamoto M; Oikawa T
    Br J Cancer; 1998 Sep; 78(6):718-23. PubMed ID: 9743289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
    Swiercz R; Wolfe JD; Zaher A; Jankun J
    Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
    Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
    Evans CP; Elfman F; Parangi S; Conn M; Cunha G; Shuman MA
    Cancer Res; 1997 Aug; 57(16):3594-9. PubMed ID: 9270033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
    Li T; Jiang S
    Pharm Biol; 2010 Feb; 48(2):161-5. PubMed ID: 20645833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic factors and suppression of metastatic ability of v-Ha-ras-transfected rat mammary cancer cells.
    Ichikawa T; Ichikawa Y; Isaacs JT
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1607-10. PubMed ID: 1542651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.